as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission. SHARE THIS POST Marinus Pharmaceuticals NewsMORE your …
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
Leave a reply